Analyst Yun Zhong of Wedbush maintained a Buy rating on Rocket Pharmaceuticals, retaining the price target of $16.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Yun Zhong has given his Buy rating due to a combination of factors surrounding Rocket Pharmaceuticals’ progress with RP-A501. The lifting of the FDA clinical hold on the pivotal Phase 2 study for Danon disease marks a significant advancement, reducing uncertainties and potentially derisking the study. The recalibrated dosing regimen, based on Phase 1 data, is expected to enhance the safety and efficacy profile, which could support future regulatory approval.
Furthermore, the management’s plan to resume patient dosing in 2026, with a structured timeline for completion, indicates a clear path forward. The anticipation of FDA data review by late 2026 and the potential for FDA approval by 2028 further strengthens the investment case. These developments suggest a promising outlook for Rocket Pharmaceuticals, justifying the Buy rating.
In another report released on August 20, Chardan Capital also maintained a Buy rating on the stock with a $11.00 price target.
Based on the recent corporate insider activity of 52 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of RCKT in relation to earlier this year.